Cargando…
Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470221/ https://www.ncbi.nlm.nih.gov/pubmed/34574696 http://dx.doi.org/10.3390/ijerph18189774 |
_version_ | 1784574143151210496 |
---|---|
author | Blum, Kenneth Gold, Mark S. Llanos-Gomez, Luis Jalali, Rehan Thanos, Panayotis K. Bowirrat, Abdalla Downs, William B. Bagchi, Debasis Braverman, Eric R. Baron, David Roy, Alphonso Kenison Badgaiyan, Rajendra D. |
author_facet | Blum, Kenneth Gold, Mark S. Llanos-Gomez, Luis Jalali, Rehan Thanos, Panayotis K. Bowirrat, Abdalla Downs, William B. Bagchi, Debasis Braverman, Eric R. Baron, David Roy, Alphonso Kenison Badgaiyan, Rajendra D. |
author_sort | Blum, Kenneth |
collection | PubMed |
description | Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise to reduce total fat mass. However, medications may have significant side effects and can be potentially fatal. Data Retrieval: This brief review, based on a PUBMED search of the key terms “Obesity” and” Sarcopenia,” will present evidence to corroborate the existence of Reward Deficiency Syndrome (RDS) in obesity and the involvement of catecholaminergic pathways in substance seeking behavior, particularly as it relates to carbohydrates cravings. Expert Opinion: The genetic basis and future genetic testing of children for risk of aberrant generalized craving behavior are considered a prevention method. Here we present evidence supporting the use of precursor amino acid therapy and modulation of enkephalinase, MOA, and COMT inhibition in key brain regions. Such treatments manifest in improved levels of dopamine/norepinephrine, GABA, serotonin, and enkephalins. We also present evidence substantiating insulin sensitivity enhancement via Chromium salts, which affect dopamine neuronal synthesis regulation. We believe our unique combination of natural ingredients will influence many pathways leading to the promotion of well-being and normal healthy metabolic functioning. Sarcopenia has been shown to reduce angiogenesis and possible cerebral blood flow. Exercise seems to provide a significant benefit to overcome this obesity-promoting loss of muscle density. Conclusion: Utilization of proposed nutrigenomic formulae based on coupling genetic obesity risk testing promotes generalized anti-craving of carbohydrates and can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention. |
format | Online Article Text |
id | pubmed-8470221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84702212021-09-27 Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? Blum, Kenneth Gold, Mark S. Llanos-Gomez, Luis Jalali, Rehan Thanos, Panayotis K. Bowirrat, Abdalla Downs, William B. Bagchi, Debasis Braverman, Eric R. Baron, David Roy, Alphonso Kenison Badgaiyan, Rajendra D. Int J Environ Res Public Health Article Background: The United States Centers for Disease Control and Prevention (CDC) estimates a total obesity rate of 30% for 12 states and a 20% obesity rate nationwide. The obesity epidemic continues to increase in spite of preventative measures undertaken worldwide. Pharmacological treatments promise to reduce total fat mass. However, medications may have significant side effects and can be potentially fatal. Data Retrieval: This brief review, based on a PUBMED search of the key terms “Obesity” and” Sarcopenia,” will present evidence to corroborate the existence of Reward Deficiency Syndrome (RDS) in obesity and the involvement of catecholaminergic pathways in substance seeking behavior, particularly as it relates to carbohydrates cravings. Expert Opinion: The genetic basis and future genetic testing of children for risk of aberrant generalized craving behavior are considered a prevention method. Here we present evidence supporting the use of precursor amino acid therapy and modulation of enkephalinase, MOA, and COMT inhibition in key brain regions. Such treatments manifest in improved levels of dopamine/norepinephrine, GABA, serotonin, and enkephalins. We also present evidence substantiating insulin sensitivity enhancement via Chromium salts, which affect dopamine neuronal synthesis regulation. We believe our unique combination of natural ingredients will influence many pathways leading to the promotion of well-being and normal healthy metabolic functioning. Sarcopenia has been shown to reduce angiogenesis and possible cerebral blood flow. Exercise seems to provide a significant benefit to overcome this obesity-promoting loss of muscle density. Conclusion: Utilization of proposed nutrigenomic formulae based on coupling genetic obesity risk testing promotes generalized anti-craving of carbohydrates and can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention. MDPI 2021-09-16 /pmc/articles/PMC8470221/ /pubmed/34574696 http://dx.doi.org/10.3390/ijerph18189774 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Blum, Kenneth Gold, Mark S. Llanos-Gomez, Luis Jalali, Rehan Thanos, Panayotis K. Bowirrat, Abdalla Downs, William B. Bagchi, Debasis Braverman, Eric R. Baron, David Roy, Alphonso Kenison Badgaiyan, Rajendra D. Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? |
title | Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? |
title_full | Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? |
title_fullStr | Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? |
title_full_unstemmed | Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? |
title_short | Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction? |
title_sort | hypothesizing nutrigenomic-based precision anti-obesity treatment and prophylaxis: should we be targeting sarcopenia induced brain dysfunction? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470221/ https://www.ncbi.nlm.nih.gov/pubmed/34574696 http://dx.doi.org/10.3390/ijerph18189774 |
work_keys_str_mv | AT blumkenneth hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT goldmarks hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT llanosgomezluis hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT jalalirehan hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT thanospanayotisk hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT bowirratabdalla hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT downswilliamb hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT bagchidebasis hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT bravermanericr hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT barondavid hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT royalphonsokenison hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction AT badgaiyanrajendrad hypothesizingnutrigenomicbasedprecisionantiobesitytreatmentandprophylaxisshouldwebetargetingsarcopeniainducedbraindysfunction |